TRIPS and China Essay by writingsensation

TRIPS and China
This paper is a literature review about the relationship of the regulations of the Trade Related Aspects of Intellectual Property (TRIPS) to intellectual property protection in China especially in the area of pharmaceuticals.
# 68243 | 2,805 words | 2 sources | APA | 2005 | US
Published on Aug 10, 2006 in Business (Law) , Business (International) , Law (International)


$19.95 Buy and instantly download this paper now

Description:

This paper discusses the regulations of TRIPS section by section. The author points out that in developing countries, little respect is given to the protection of rights associated with intellectual property, especially in the area of generic and counterfeit medications, which pirate patented drugs. This becomes a particular problem in China because of the size of its population. The paper concludes that within five years China and other WTO countries will have a decrease in the infringement of intellectual property; however, the China's government will have to implement more extensive reforms in order to liberalize the domestic market in China and to allow China and other foreign companies to import and export products more freely.

Table of Contents
Statement of Thesis
Introduction
Regulations of TRIPS
Exploration of the Domestic Implementations of TRIPS in Main Developed and Developing Countries
The Chinese IP Protection and TRIPS and the Problems/Impact and Recommendations of Actions to Improve
General Provisions and Basic Principles
Copyright and Related Rights
TRIPS and Public Health
TRIPS and the Convention on Biological Diversity
Summary
Conclusion

From the Paper:

"U.S. pharmaceutical and biotechnology companies invested the approximate amount of $33.2 billion toward activities of research and development which is about 18% of the sales total of all their combined products. The discovery costs in pre-tax amounts of a new drug experienced an increase from $500 million to $880 million between 1990 and 2003 and as well the time of waiting for approval and the like has grown in length due to regulatory requirements and other associated technicalities. In order to limit the risk in the activities related to therapeutic areas the U.S. companies must find business partners and associates in China and other countries who are trustworthy."

Cite this Essay:

APA Format

TRIPS and China (2006, August 10) Retrieved August 09, 2020, from https://www.academon.com/essay/trips-and-china-68243/

MLA Format

"TRIPS and China " 10 August 2006. Web. 09 August. 2020. <https://www.academon.com/essay/trips-and-china-68243/>

Comments